Biography

Dr. Satish Chandran is a biotechnology executive with more than 30 years of leadership experience across academic research, early- and mid-stage biotechs, and large pharmaceutical companies. Since 2021 he has served as CEO and Board member of Prodigy Biotech focused on developing microbiome-modulating products for various disease indications. He is the founder of Somahlution, a company focused on developing novel products for cardiac surgery and transplantation, where he served as CEO and Board member from its inception in 2010 until its acquisition by Marizyme, Inc. in 2020. Following the acquisition, Dr. Chandran served as Marizyme’s President and Chief Technology Officer until 2021.

Earlier in his career, Dr. Chandran was Chief Technology Officer at Pfizer Biotherapeutics-OTU, where he led programs in oncology and metabolic diseases. Prior to that, he co-founded Nucleonics, Inc., a company based on his discoveries in RNA interference, serving as Chief Operating Officer and Chief Scientific Officer. He also directed the nucleic acid vaccine group at Wyeth Vaccines, following Wyeth’s acquisition of Apollon, Inc., where he had led the development of nucleic acid-based vaccine candidates.

Dr. Chandran began his career in academic research at Fox Chase Cancer Center in Philadelphia and has held faculty appointments at Thomas Jefferson University, Blumberg Institute for Viral Hepatitis Research, and North Dakota State University—where he was Director of the Center of Excellence for Biopharmaceutical Research and Development.

Dr. Chandran earned his Ph.D. from Memorial University in Newfoundland, Canada, and completed his post-doctoral fellowship at Fox Chase Cancer Center. He is the author of numerous scientific publications and holds several patents in the fields of vaccines, biologics and medical devices. Dr. Chandran currently serves on the boards of several biotechnology companies, including Prodigy Bio, Lay Sciences, Statera Biopharma, and Avstera.